Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized Trial | Zendy

Jiang Wu | Zendy; Han-hua Fang | Zendy; Jiangting Chen | Zendy; Jichen Zhou | Zendy; ZiJian Feng | Zendy; ChangGui Li | Zendy; Yuan-zheng Qiu | Zendy; Yan Liu | Zendy; Min Lü | Zendy; Liying Liu | Zendy; ShanShan Dong | Zendy; Qiang Gao | Zendy; Xiaomei Zhang | Zendy; Nan Wang | Zendy; Weidong Yin | Zendy; XiaoPing Dong | Zendy

Open Access

Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized Trial

Author(s) -

Jiang Wu,

Han-hua Fang,

Jiangting Chen,

Jichen Zhou,

ZiJian Feng,

ChangGui Li,

Yuan-zheng Qiu,

Yan Liu,

Min Lü,

Liying Liu,

ShanShan Dong,

Qiang Gao,

Xiaomei Zhang,

Nan Wang,

Weidong Yin,

XiaoPing Dong

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597401

Subject(s) - hemagglutination assay , medicine , seroconversion , immunogenicity , virology , inactivated vaccine , influenza a virus subtype h5n1 , vaccination , titer , influenza vaccine , live attenuated influenza vaccine , hemagglutinin (influenza) , immunology , immune system , virus

Avian influenza A virus H5N1 has the potential to cause a pandemic. Adjuvants and whole-virion vaccines are regarded as antigen sparing for pandemic vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research